DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

Are Biosimilars the Next Big Thing in Biotech?

Biosimilars could soon become a major force in biotech as multiple top-selling biologics lose patent protection. So are biosimilars the next big thing in biotech, or are they overhyped?

Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog

AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog

Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More

Today's Top Performers In Drugs

Illumina's Earnings Set Positive Tone for Biotech

What's behind Illumina's remarkable earnings beat, and what could it mean for biotech stocks?

Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story

Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

IHE, MRK, BMY, LLY: Large Inflows Detected at ETF

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?

Immuno-oncology has become a major focus among big pharma companies these days. Should investors jump on this trend?
See More Articles...